Skip to main content Back to Top
Advertisement

11/22/2017

Gentamicin Injection

Products Affected - Description

    • Gentamicin injection, Pfizer, 60 mg/50 mL, premixed bag, 24 count, NDC 00409-7879-13

Reason for the Shortage

    • Pfizer has discontinued all premixed bags.
    • Baxter did not provide a reason for the shortage.

Available Products

    • Gentamicin injection, Baxter, 100 mg/100 mL, premixed bag, 24 count, NDC 00338-0505-48
    • Gentamicin injection, Baxter, 100 mg/50 mL, premixed bag, 24 count, NDC 00338-0511-41
    • Gentamicin injection, Baxter, 120 mg/100 mL, premixed bag, 24 count, NDC 00338-0507-48
    • Gentamicin injection, Baxter, 60 mg/50 mL, premixed bag, 24 count, NDC 00338-0507-41
    • Gentamicin injection, Baxter, 80 mg/100 mL, premixed bag, 24 count, NDC 00338-0503-48
    • Gentamicin injection, Baxter, 80 mg/50 mL, premixed bag, 24 count, NDC 00338-0509-41
    • Gentamicin injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0173-02
    • Gentamicin injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0010-02
    • Gentamicin injection, Fresenius Kabi, 40 mg/mL, 20 mL vial, 25 count, NDC 63323-0010-20
    • Gentamicin injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-1207-03

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 22, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 3, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins